NeoImmuneTech, Inc. (KOSDAQ:950220)
South Korea · Delayed Price · Currency is KRW 576.00
+2.00 (0.35%)
Oct 31, 2025, 1:40 PM KST
NeoImmuneTech Company Description
NeoImmuneTech, Inc., a clinical-stage T cell-focused biotech company, develops and sells immuno-therapeutics.
It is developing NT-I7, a clinical-stage long-acting human IL-7 for oncologic and infectious diseases.
The company was incorporated in 2014 and is headquartered in Rockville, Maryland.
NeoImmuneTech, Inc.
| Country | South Korea |
| Founded | 2014 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 52 |
| CEO | Luke Yun Oh |
Contact Details
Address: 2400 Research Blvd. Rockville, 20850 United States | |
| Phone | 240 801 9065 |
| Website | neoimmunetech.com |
Stock Details
| Ticker Symbol | 950220 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR8840140006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Luke Yun Oh | Chief Executive Officer |
| Tae Woo Kim | Chief Financial Officer |
| Goongjin Namgoong | Chief Operating Officer |